Gradalis® - Personalized Cancer Immunotherapy Gradalis is a late stage biotechnology company focused on the development and commercialization of novel personalized therapeutics to treat cancer
Gradalis, Inc. - LinkedIn Gradalis is a late-stage clinical biotechnology company developing immunotherapies for multiple cancer indications including an upcoming Phase 3 registration trial in patients with ovarian cancer
Gradalis - 2026 Company Profile Team - Tracxn Gradalis is a series C company based in Carrollton (United States), founded in 2010 by John Nemunaitis and John Nemunaitis MD It operates as a Personalized cancer immunotherapy company advancing treatment through Vigil platform
Gradalis GRAD bi-shRNAi Candidate First to Show Positive Impact on . . . Founded in 2006, Gradalis is a privately held, clinical-stage biotechnology company developing a new category of personalized therapies based on proprietary bi-shRNAi technology It’s lead product, called Vigil, is an immunotherapy that has been tested in multiple studies in ovarian and other cancer tumor types
FDA gives RMAT status to Vigil immunotherapy for ovarian cancer Gradalis is developing Vigil as a maintenance treatment for ovarian cancer that’s stage 3b or 4 — cancer that has started to spread to other parts of the body — in patients whose cancer is homologous recombination proficient and has a high clonal tumor mutation burden
Gradalis - Teacher Education Gradalis Professional Development Training is a nationally accredited institution Gradalis Training Programs qualify across state lines for required hours to maintain teaching certifications
Gradalis, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Founded in 2006, Gradalis is a privately held, clinical-stage biotechnology company developing a new category of personalized therapies based on proprietary bi-shRNAi technology Its lead product, called Vigil, is an immunotherapy that has been tested in multiple studies in ovarian and other cancer tumor types